FNCH Company Profile and Key Details

Q: Who are the executives of FNCH?

Dr. Alka Batycky Ph.D.Chief Devel. OfficerMr. James S. SiglerExecutive Vice President of CMCDr. Howard Franklin M.B.A., M.D.Chief Medical OfficerMr. Matthew P. BlischakChief Executive OfficerMr. Lance Thibault C.P.A., CPAChief Financial OfficerDr. Mark Burnham Smith Ph.D.Chief Executive Officer & DirectorMr. Marc B. Blaustein C.F.A., CFA, MPPChief Operating Officer and Principal Financial & Accounting OfficerMs. Sonia TimberlakeSenior Vice President of ResearchMr. Bryan Gillis M.B.A.Chief Technology OfficerMatt Nelson M.B.A.Vice President of Fin.Dr. Howard J. Franklin M.B.A., M.D.Senior Vice President of MedicalMr. Matthew P. Blischak J.D.Chief Executive OfficerMr. Lance Thibault CPA, CPAActing Vice President of Fin.Mr. James S. Sigler MBAExecutive Vice President of CMC

NASDAQ : FNCH

Finch Therapeutics Group

$13.40

-0.35-2.55%

At Close 4:00 PM

63.43

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Finch Therapeutics Group, Inc. (FNCH) stock declined over -2.55%, trading at $13.40 on OTC, down from the previous close of $13.75. The stock opened at $13.75, fluctuating between $13.30 and $14.00 in the recent session.

Stock Snapshot

13.75

Prev. Close

21.52M

Market Cap

13.3

Day Low

-1.52

P/E Ratio

-8.8

EPS (TTM)

-19.62

Cash Flow per Share

13.75

Open

1.61M

Number of Shares

Day High

55.81%

Free Float in %

14.25

Book Value

2.09K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Dec 22, 2025	13.75	13.77	13.40	13.40	4K
Dec 19, 2025	14.00	14.00	13.75	13.83	1.19K
Dec 17, 2025	13.50	13.50	13.40	13.40	901
Dec 16, 2025	13.50	13.98	13.50	13.50	3.67K
Dec 15, 2025	13.55	13.55	13.44	13.44	3.56K
Dec 12, 2025	13.80	13.98	13.56	13.98	3.89K
Dec 10, 2025	13.98	13.98	13.98	13.98	1K
Dec 09, 2025	13.88	14.20	13.65	13.70	2.92K
Dec 08, 2025	13.51	14.20	13.51	13.78	3.69K
Dec 05, 2025	13.50	14.20	13.50	14.20	4.97K
Dec 04, 2025	13.35	14.75	13.35	13.62	9.78K
Dec 03, 2025	13.41	16.10	13.30	13.30	40.75K
Dec 02, 2025	13.42	13.45	13.42	13.45	2.67K
Dec 01, 2025	13.42	13.42	13.42	13.42	4
Nov 26, 2025	13.51	13.51	13.51	13.51	116
Nov 25, 2025	13.56	13.99	13.56	13.99	3.22K
Nov 24, 2025	13.63	14.00	13.56	14.00	1.25K
Nov 21, 2025	13.80	14.00	13.63	13.65	2.05K
Nov 19, 2025	14.02	14.02	13.55	13.80	11.69K
Nov 18, 2025	14.02	14.02	14.02	14.02	2

Contact Details

Somerville, MA 02143

United States

https://www.finchtherapeutics.com 617 229 6499

About Company

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 TLPPF

Telix Pharmaceuticals Limited$11.00

Frequently Asked Questions

What is the current Finch Therapeutics Group, Inc. (FNCH) stock price?

Finch Therapeutics Group, Inc. (OTC: FNCH) stock price is $13.40 in the last trading session. During the trading session, FNCH stock reached the peak price of $14.00 while $13.30 was the lowest point it dropped to. The percentage change in FNCH stock occurred in the recent session was -2.55% while the dollar amount for the price change in FNCH stock was - $0.35.

FNCH's industry and sector of operation?

The OTC listed FNCH is part of Biotechnology industry that operates in the broader Healthcare sector. Finch Therapeutics Group, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FNCH?

Dr. Alka Batycky Ph.D.
Chief Devel. Officer
Mr. James S. Sigler
Executive Vice President of CMC
Dr. Howard Franklin M.B.A., M.D.
Chief Medical Officer
Mr. Matthew P. Blischak
Chief Executive Officer
Mr. Lance Thibault C.P.A., CPA
Chief Financial Officer
Dr. Mark Burnham Smith Ph.D.
Chief Executive Officer & Director
Mr. Marc B. Blaustein C.F.A., CFA, MPP
Chief Operating Officer and Principal Financial & Accounting Officer
Ms. Sonia Timberlake
Senior Vice President of Research
Mr. Bryan Gillis M.B.A.
Chief Technology Officer
Matt Nelson M.B.A.
Vice President of Fin.
Dr. Howard J. Franklin M.B.A., M.D.
Senior Vice President of Medical
Mr. Matthew P. Blischak J.D.
Chief Executive Officer
Mr. Lance Thibault CPA, CPA
Acting Vice President of Fin.
Mr. James S. Sigler MBA
Executive Vice President of CMC

How FNCH did perform over past 52-week?

FNCH's closing price is 32.02% higher than its 52-week low of $10.15 where as its distance from 52-week high of $16.10 is -16.77%.

How many employees does FNCH have?

Number of FNCH employees currently stands at 1.

Link for FNCH official website?

Official Website of FNCH is: https://www.finchtherapeutics.com

How do I contact FNCH?

FNCH could be contacted at phone 617 229 6499 and can also be accessed through its website. FNCH operates from 200 Inner Belt Road, Somerville, MA 02143, United States.

How many shares of FNCH are traded daily?

FNCH stock volume for the day was 2.09K shares. The average number of FNCH shares traded daily for last 3 months was 4.46K.

What is the market cap of FNCH currently?

The market value of FNCH currently stands at $21.52M with its latest stock price at $13.40 and 1.61M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	1
Beta	1.16
Sales or Revenue	$107.00K
5Y Sales Change%	-0.989%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	1
Beta	1.16
Sales or Revenue	$107.00K
5Y Sales Change%	-0.989%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FNCH Company Profile and Key Details

Finch Therapeutics Group

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Technical Performance

Dividend & Fair Value

Company Overview

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook

Valuation Metrics